Infex Therapeutics to begin clinical development of anti-virulence therapy for Pseudomonas aeruginosa (Pa) in non-cystic fibrosis bronchiectasis patients
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022…
Infex welcomes NICE and NHS England’s new antibiotic reimbursement mechanism
Alderley Park, Cheshire - Infex Therapeutics, one of the UK’s leading…
Infex scientists achieve breakthrough to overcome critical priority drug resistant infections
Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech…
Infex agrees partnership with Colibri Scientific to provide services for RESP-X program
Alderley Park, Cheshire Infex Therapeutics has today announced a deal with…
Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains
Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech…
Budget’s R&D investment increase must propel action on AMR, says Dr Peter Jackson of Infex Therapeutics
Commenting in reaction to the Chancellor’s budget on 27th October 2021, Dr…
Infex Therapeutics sharpens Covid focus with new CRUK Newcastle partnership
Alderley Park, Cheshire - Infex Therapeutics is pressing ahead with a major…
Tackling underlying respiratory conditions for this pandemic and next
During the COVID-19 pandemic, one of the many phrases that has become…
Infex partners with Alderley Analytical to provide PK and ADA analysis for RESP-X program
Alderley Park, Cheshire Infex Therapeutics has today announced a deal with…
Infex appoints Lonza to manufacture new lung infection drug
Alderley Park, Cheshire Infex Therapeutics has awarded a £1m contract to Lonza…